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ABSTRACT
Introduction: Congenital heart diseases (CHD) are
common causes of cardiovascular morbidity and
mortality among young children and adolescents
living in Africa. Accurate epidemiological data
are needed in order to evaluate and improve
preventive strategies. This review aims to determine
the prevalence of CHD and their main patterns
in Africa.
Methods and analysis: This systematic review and
meta-analysis will include cross-sectional, case–control
and cohort studies of populations residing inside
African countries, which have reported the prevalence
of CHD, confirmed by an echocardiographic
examination and/or describing different patterns of
these abnormalities in Africa. Relevant abstracts
published without language restriction from 1 January
1986 to 31 December 2016 will be searched in
PubMed, Exerpta Medica Database and online African
journals as well as references of included articles and
relevant reviews. Two review authors will independently
screen, select studies, extract data and assess the risk
of bias in each study. The study-specific estimates will
be pooled through a random-effects meta-analysis
model to obtain an overall summary estimate of the
prevalence of CHD across studies. Clinical and
statistical heterogeneity will be assessed, and we will
pool studies judged to be clinically homogeneous. On
the other hand, statistical heterogeneity will be
evaluated by the χ2 test on Cochrane’s Q statistic.
Funnel-plots analysis and Egger’s test will be used to
detect publication bias. Results will be presented by
geographic region (central, eastern, northern, southern
and western Africa).
Ethics and dissemination: The current study will be
based on published data, and thus ethical approval is
not required. This systematic review and meta-analysis
is expected to serve as a base which could help in
estimating and evaluating the burden of these
abnormalities on the African continent. The final report
of this study will be published in a peer-reviewed
journal.
Trial registration number: PROSPERO
CRD42016052880.
INTRODUCTION
Congenital heart disease or congenital heart
defect (CHD) is a problem of the heart’s
structure and function present at birth,
affecting the heart or adjacent great blood
vessels, detected either at the time of birth
or detected later in life.1 2 Worldwide, CHD
are the main heart diseases found in chil-
dren and constitute one of the major causes
of infant mortality, particularly in developing
countries.2 3 They also represent the most
common of all congenital malformations
accounting for more than 20% of perinatal
deaths.4 5 Their estimated prevalence is eight
cases per 1000 live births across the globe,
representing ∼1.35 million newborns each
year with CHD, but these ﬁgures vary world-
wide.2 For instance, the incidence of CHD in
different studies varies from about 4/1000 to
50/1000 live births and, despite advances in
detection and treatment, congenital heart
diseases account for 3% of all infant deaths
and 46% of deaths from congenital malfor-
mations in developed countries such as the
Strengths and limitations of this study
▪ To the best of our knowledge, this will be the
first systematic review on the topic of congenital
heart diseases (CHD) to summarise available
data on the African continent.
▪ We will use powerful meta-analysis techniques to
derive accurate estimates.
▪ A major possible limitation of this study could
be the limited data with predominance of
hospital-based studies. Indeed, these studies
may not reflect the true prevalence of CHD in the
general population, therefore overestimating
these estimates.
▪ Another possible limitation may be heterogeneity
of studies carried out on the topic in Africa.
Tankeu AT, et al. BMJ Open 2017;7:e015633. doi:10.1136/bmjopen-2016-015633 1
Open Access Protocol
USA.4–6 In addition, these abnormalities can be life-
threatening in early childhood, and children born with
severe forms are at ∼12 times higher risk of mortality in
the ﬁrst year of life.7 Thus, hundreds of thousands of
children die each year from CHD, while millions more
remain in desperate need of treatment in the develop-
ing world.8 Since mortality and morbidity from cardiac
disease among children in developing countries are
gaining recognition, there is a need of summarised data
on CHD in the African continent. Africa is thought to
have one of the highest prevalences of heart diseases in
children and young adults, including CHD, but the
main ﬁndings include evidence that the CHD burden is
underestimated mainly due to the poor outcome of
African children with CHD.7 From a global point of
view, the epidemiology of these abnormalities is still
unknown in Africa with few data on the topic. Reducing
the prevalence of these diseases is urgent and requires a
real inventory of the premises of the problem that would
clarify the issue for more effective prevention strategies
and improved management. In this context, we present
the protocol for a systematic review and meta-analysis to
assess the prevalence and patterns of CHD in Africa.
OBJECTIVE
This systematic review and meta-analysis aims to deter-
mine the prevalence of CHD and their different pat-
terns in Africa.
Review question
This review of studies published in the past 30 years,
from 1 January 1986 to 31 December 2016, should
answer the following questions:
1. What is the prevalence of CHD among African
populations?
2. What are the different patterns of CHD in Africa?
METHODS AND ANALYSIS
Criteria for considering studies for the review
Inclusion criteria
We will include:
1. Cross-sectional, case–control or cohort studies of
populations residing in African countries reporting
the prevalence of CHD in African countries or
enough data to compute these estimates, regardless
of stillbirth.
2. Studies describing the different patterns of CHD on
the African continent.
Exclusion criteria
We will not consider:
1. Studies on congenital abnormalities involving the
heart but not considered as CHD (Long QT syn-
drome, congenital but functionless abnormalities of
the heart, cardiomyopathies).
2. Studies conducted among populations of African
origin residing outside Africa.
3. Studies in subgroups of participants selected on the
basis of cardiac murmurs without echocardiographic
conﬁrmation of CHD (eg, suspected but non-
conﬁrmed CHD).
4. Studies including many pathologies in which it will
not be possible to extract data regarding CHD or
studies reporting congenital abnormalities affecting
many systems at a time.
5. Letters, reviews, commentaries and editorials.
6. Studies lacking key data and/or explicit method
description.
7. Duplicates: for studies published in more than one
paper, the most comprehensive one reporting the
largest sample size will be considered.
8. Studies whose full data will not be accessible even
after request from the authors.
Search strategy for identifying relevant studies
The search strategy will be implemented in two stages:
Bibliographic database searches
(A) Relevant abstracts published without language
restriction on the prevalence, incidence, main aetiolo-
gies and clinical features of CHD in Africa will be iden-
tiﬁed via a search of PubMed, Exerpta Medica Database
and online African journals. The search will be limited
to studies published between 1 January 1986 and 31
December 2016. Both text words and medical subject
heading terms will be used. Key search terms include:
‘congenital heart defects’ or ‘congenital heart disease’
as well as the name of every known pattern of these
abnormalities. We will also use individual country
names for the 54 African countries as additional key
search terms for more abstracts on the subject.
Conference proceedings and studies from grey literature
of the study period will also be identiﬁed through data-
bases and checked. The main search strategy is shown
in table 1.
(B) The abstracts of all eligible papers will be reviewed
and full articles will be accessed through PubMed,
Exerpta Medica Database, Google Scholar, HINARI or
journals’ websites. Additionally, references of all relevant
articles and reviews will be scrutinised for other poten-
tial data sources and their full texts will be accessed in a
similar way. The authors whose full text papers will not
be accessible by the numerous internet-based sources
will be directly contacted to provide them. In case of no
feedback from these authors, the corresponding studies
will be excluded.
Searching for other sources
References of all relevant researches and review articles
will be scrutinised for additional potential data sources,
and their full texts will be accessed in a similar way.
Those authors whose full text papers will not be access-
ible by the numerous internet-based sources will be dir-
ectly contacted via email to provide them. In case of no
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feedback from these authors, the corresponding studies
will be excluded.
Selection of studies for inclusion in the review
Assessment of eligible papers will be independently
carried out by two authors using an assessment guide
to ensure that the selection criteria are reliably
applied by all the team members. They will screen
the titles and abstracts obtained from the searches
and retrieve the full texts of potentially eligible papers
by at least one author. Thereafter, they will independ-
ently review the full text of each potentially eligible
study, compare their results and resolve any discrep-
ancy by discussion and consensus. If a decision is not
reached, a third review author will be consulted for
arbitration.
Assessment of methodological quality and reporting
of data
The Newcastle-Ottawa Scale for assessing the quality of
non-randomised studies in meta-analyses will be used to
assess the methodological quality and risk of bias for
each study (see online supplementary appendix S1).9
Risk of bias and quality scores will be presented in a
table.
Data extraction and management
A data extraction sheet will be used to collect informa-
tion about the author, the country, the year of publica-
tion, the study design, the sample size population, the
mean/median age of the population, the age range, the
sex ratio, the prevalence of CHD as well as main pat-
terns when available. Where prevalence or information
for calculating them (eg, sample size, number of out-
comes) is lacking, we will directly contact the corre-
sponding author and request the information. In case of
multinational studies, we will separate the results to show
the prevalence and aetiologies within individual coun-
tries. Where it will not be possible to disaggregate the
data by country, the study will be presented as one and
the countries in which the study was carried out will be
shown.
Data synthesis and analysis
Data will be analysed using Stata software V.13 (Stata
Corp V.13, Texas, USA). A meta-analysis will be con-
ducted for data obtained from studies in which CHD has
the same aetiologies, and SEs for the study-speciﬁc esti-
mates will ﬁrst be determined from the point estimate
and the appropriate denominators, assuming a binom-
inal distribution. Then the study-speciﬁc estimates will be
Table 1 Search strategy for PubMed
Search
(numbers) Search terms
1 congenital heart OR heart defects OR heart murmur OR fallot OR ventricular defect OR atrial defect OR septal
defect OR great vessels transposition OR foramen ovale OR single ventricle OR persistent ductus arteriosus OR
dorv OR avsd OR ASD OR VSD OR BAV OR d-tga OR aorta coarctation OR hypoplastic heart OR total
anomalous pulmonary venous connection OR truncus arteriosus OR Ebstein’s abnormality OR tricuspid atresia
OR cyanotic heart OR non cyanotic heart OR mitral stenosis[tw] OR mitral incompetence[tw] OR tricuspid
incompetence[MeSH terms] OR tricuspid stenosis[tw] OR pulmonary stenosis[tw] OR pulmonary incompetence
[tw] OR aortic incompetence[tw] OR aortic stenosis[MeSH terms] OR heart murmur[tw] OR Atrial septal defect
[tw] OR Ventricular septal defect[tw] OR Pulmonary atresia[tw] OR Aortic atresia[tw] OR echocardiography
abnormalities[tw] OR Fallot tetralogy[tw] OR aorta coarctation[tw] OR cyanotic cardiac abnormalities[tw] OR
atrioventricular septal defects[tw] OR biscupid aortic valve[tw] OR double outlet right ventricle[tw] OR patent
ductus arteriosus[tw] OR single ventricle[tw] OR great arteries transposition[tw] OR hypoplastic heart[tw] OR
tricuspid atresia[tw] OR Ebstein abnormality[tw] OR truncus arteriosus[tw] OR total anomalous pulmonary
venous connection[tw]
2 (Africa* OR Algeria OR Angola OR Benin OR Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR
“Canary Islands” OR “Cape Verde” OR “Central African Republic” OR Chad OR Comoros OR Congo OR
“Democratic Republic of Congo” OR Djibouti OR Egypt OR “Equatorial Guinea” OR Eritrea OR Ethiopia OR
Gabon OR Gambia OR Ghana OR Guinea OR “Guinea Bissau” OR “Ivory Coast” OR “Cote d’Ivoire” OR
Jamahiriya OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania
OR Mauritius OR Mayotte OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR
Reunion OR Rwanda OR “Sao Tome” OR Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR “South
Africa” OR “South Sudan” OR “St Helena” OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR
Uganda OR “Western Sahara” OR Zaire OR Zambia OR Zimbabwe OR “Central Africa” OR “Central African” OR
“West Africa” OR “West African” OR “Western Africa” OR “Western African” OR “East Africa” OR “East African”
OR “Eastern Africa” OR “Eastern African” OR “North Africa” OR “North African” OR “Northern Africa” OR
“Northern African” OR “South African” OR “Southern Africa” OR “Southern African” OR “sub Saharan Africa” OR
“sub Saharan African” OR “subSaharan Africa” OR “subSaharan African”) NOT (“guinea pig” OR “guinea pigs”
OR “aspergillus niger”)
3 #1 AND #2
4 # 3 Limits: : 1986/01/01 to 2016/12/31
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pooled through a random-effects meta-analysis model to
obtain an overall summary estimate of the prevalence
across studies, after stabilising the variance of individual
studies using the Freeman-Tukey double arc-sine trans-
formation (to keep the effect of studies with extremely
small or large estimates).10 Heterogeneity will be evalu-
ated by the χ² test on Cochrane’s Q statistic11 which is
quantiﬁed by I² values, assuming that I² values of 25%,
50% and 75% represent low, medium and high hetero-
geneity, respectively.12 Where substantial heterogeneity
will be detected, a subgroup analysis will be performed
to detect its possible sources using the following group-
ing variables: type of CHD, consequences on cardiac
haemodynamic, study setting (hospital vs community-
based), age of diagnosis, geographical area (central,
eastern, northern, southern and western Africa) and
study quality. Difference between groups will be detected
if p value<0.05. Inter-rater agreement for study inclusion
will be assessed using Cohen’s κ coefﬁcient.13 Funnel
plots analysis and Egger’s test14 will be performed to
detect publication bias. Publication bias will be con-
ﬁrmed if p value on Egger’s test<0.10. Results will be pre-
sented by geographic region (central, eastern, northern,
southern and western Africa).
PRESENTATION AND REPORTING OF RESULTS
The study selection process will be summarised using a
ﬂow diagram. Reasons for studies’ exclusion will be
described. The report will follow the Preferred
Reporting Items for systematic review and Meta-analysis
(PRISMA) Guidelines.15 Tables and forest plots will
serve to summarise quantitative data where appropriate.
We will examine prevalence and aetiologies by region,
setting (hospital or community) and time period
depending on the data available. We plan to report on
quality scores and risk of bias for each eligible study.
This may be tabulated and accompanied by narrative
summaries.
CONCLUSION
CHD represent the second major cause of cardiovascu-
lar disease morbidity and mortality among young
Africans. Their management is limited in Africa in an
inadequate socioeconomic environment with an insufﬁ-
cient technical platform and human resources.
Moreover, the global burden of these conditions is
unknown on the continent. Therefore, it becomes
urgent to provide summarised recent and reliable data
in order to help estimate the prevalence as well as
aetiologies in Africa in order to highlight the import-
ance of these abnormalities and the need for
reinforcement of effective preventive strategies based
on systematic screening of cardiac abnormalities in the
perinatal period. We hope that this review will help
sensitise healthcare providers on the problem repre-
sented by CHD in Africa, assist and support the imple-
mentation of new policies, practices and researches by
providing insights into the current situation and the
true impact of CHD on the African continent as well
as shortcomings that can guide future research around
this topic.
Protocol and registration
The protocol for this review has been published in the
PROSPERO International Prospective Register of system-
atic reviews (http://www.crd.york.ac.uk/PROSPERO),
registration number: PROSPERO CRD42016052880.
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